Literature DB >> 19923904

Vaccines against tularemia.

Eileen M Barry1, Leah E Cole, Araceli E Santiago.   

Abstract

Francisella tularensis is a Category A select agent for which vaccine and countermeasure development are a priority. In the past eight years, renewed interest in this pathogen has led to the generation of an enormous amount of new data on both the pathogen itself and its interaction with host cells. This information has fostered the development of various vaccine candidates including acellular subunit, killed whole cell and live attenuated. This review summarizes the progress and promise of these various candidates.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19923904      PMCID： PMC3132883          DOI： 10.4161/hv.10297

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN： 1554-8600


  104 in total

1.  An outbreak of primary pneumonic tularemia on Martha's Vineyard.

Authors:  K A Feldman; R E Enscore; S L Lathrop; B T Matyas; M McGuill; M E Schriefer; D Stiles-Enos; D T Dennis; L R Petersen; E B Hayes
Journal:  N Engl J Med       Date:  2001-11-29       Impact factor: 91.245

2.  [Phase variations of Francisella tularensis lipopolysaccharide in human infection and immunization].

Authors:  N V Aronova; N V Pavlovich
Journal:  Zh Mikrobiol Epidemiol Immunobiol       Date:  2005 Jul-Aug

3.  Uptake of serum-opsonized Francisella tularensis by macrophages can be mediated by class A scavenger receptors.

Authors:  Lynda M Pierini
Journal:  Cell Microbiol       Date:  2006-08       Impact factor: 3.715

4.  The role of B/T costimulatory signals in the immunopotentiating activity of neisserial porin.

Authors:  F G Mackinnon; Y Ho; M S Blake; F Michon; A Chandraker; M H Sayegh; L M Wetzler
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

5.  Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.

Authors:  Shawn D Baron; Rajendra Singh; Dennis W Metzger
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

6.  Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis.

Authors:  Joann L Prior; Richard G Prior; Paul G Hitchen; Helen Diaper; Kate F Griffin; Howard R Morris; Anne Dell; Richard W Titball
Journal:  J Med Microbiol       Date:  2003-10       Impact factor: 2.472

7.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

Review 8.  Animal models of Francisella tularensis infection.

Authors:  C Rick Lyons; Terry H Wu
Journal:  Ann N Y Acad Sci       Date:  2007-03-29       Impact factor: 5.691

9.  Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia.

Authors:  M Fulop; R Manchee; R Titball
Journal:  Vaccine       Date:  1995-09       Impact factor: 3.641

Review 10.  The ecology of tularaemia.

Authors:  T Mörner
Journal:  Rev Sci Tech       Date:  1992-12       Impact factor: 1.181
View more
  18 in total

1.  Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.

Authors:  Katharina Richard; Barbara J Mann; Aiping Qin; Eileen M Barry; Robert K Ernst; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2017-03-06

2.  Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

Authors:  Katharina Richard; Barbara J Mann; Lenea Stocker; Eileen M Barry; Aiping Qin; Leah E Cole; Matthew T Hurley; Robert K Ernst; Suzanne M Michalek; Daniel C Stein; Philip Deshong; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

3.  TolC-dependent modulation of host cell death by the Francisella tularensis live vaccine strain.

Authors:  Christopher R Doyle; Ji-An Pan; Patricio Mena; Wei-Xing Zong; David G Thanassi
Journal:  Infect Immun       Date:  2014-03-10       Impact factor: 3.441

4.  Disruption of Francisella tularensis Schu S4 iglI, iglJ, and pdpC genes results in attenuation for growth in human macrophages and in vivo virulence in mice and reveals a unique phenotype for pdpC.

Authors:  Matthew E Long; Stephen R Lindemann; Jed A Rasmussen; Bradley D Jones; Lee-Ann H Allen
Journal:  Infect Immun       Date:  2012-12-28       Impact factor: 3.441

5.  Antioxidant Defenses of Francisella tularensis Modulate Macrophage Function and Production of Proinflammatory Cytokines.

Authors:  Seham M Rabadi; Belkys C Sanchez; Mrudula Varanat; Zhuo Ma; Sally V Catlett; Juan Andres Melendez; Meenakshi Malik; Chandra Shekhar Bakshi
Journal:  J Biol Chem       Date:  2015-12-07       Impact factor: 5.157

6.  Respiratory and oral vaccination improves protection conferred by the live vaccine strain against pneumonic tularemia in the rabbit model.

Authors:  Elizabeth Stinson; Le'Kneitah P Smith; Kelly Stefano Cole; Eileen M Barry; Douglas S Reed
Journal:  Pathog Dis       Date:  2016-08-09       Impact factor: 3.166

7.  Whole-genome immunoinformatic analysis of F. tularensis: predicted CTL epitopes clustered in hotspots are prone to elicit a T-cell response.

Authors:  Anat Zvi; Shahar Rotem; Erez Bar-Haim; Ofer Cohen; Avigdor Shafferman
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

Review 8.  Transmission-Blocking Vaccines: Focus on Anti-Vector Vaccines against Tick-Borne Diseases.

Authors:  Girish Neelakanta; Hameeda Sultana
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-12-12       Impact factor: 4.291

9.  Development of a Multivalent Subunit Vaccine against Tularemia Using Tobacco Mosaic Virus (TMV) Based Delivery System.

Authors:  Sukalyani Banik; Ahd Ahmed Mansour; Ragavan Varadharajan Suresh; Sherri Wykoff-Clary; Meenakshi Malik; Alison A McCormick; Chandra Shekhar Bakshi
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

10.  Clusters versus affinity-based approaches in F. tularensis whole genome search of CTL epitopes.

Authors:  Anat Zvi; Shahar Rotem; Ofer Cohen; Avigdor Shafferman
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.